Immunovant, Inc. (IMVT)
Stock Price:
$42.02 USD
1.99 (4.96%)
Updated Oct 22, 2020 1:51 PM EDT - Market open
Key Info
| Market Cap |
3.66B |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-58.43M |
| Shares Out |
87.08M |
| EPS (ttm) |
-1.18 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 22, 2020 |
| Last Price |
$42.02 |
| Previous Close |
$40.03 |
| Change ($) |
1.99 |
| Change (%) |
4.96% |
| Day's Open |
40.39 |
| Day's Range |
39.58 - 42.10 |
| Day's Volume |
86,877 |
| 52-Week Range |
8.34 - 43.94 |
More Stats
| Market Cap |
3.66B |
| Enterprise Value |
3.38B |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
87.08M |
| Float |
36.78M |
| EPS (basic) |
-1.18 |
| EPS (diluted) |
-1.18 |
| FCF / Share |
-0.95 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.37M |
| Short Ratio |
3.13 |
| Short % of Float |
6.45% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
15.21 |
| Revenue |
n/a |
| Operating Income |
-58.53M |
| Net Income |
-58.43M |
| Free Cash Flow |
-66.98M |
| Net Cash |
276.21M |
| Net Cash / Share |
3.17 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-29.32% |
| ROE |
-57.14% |
| ROIC |
-250.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (10)
| Buy |
8 |
| Overweight |
2 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$47.60*
(13.29% upside)
Low
39.0
Current: $42.02
High
63.0
Target: 47.60
*Average 12-month price target from 10 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | - |
| Operating Income | -66.08 | -28.43 |
| Net Income | -66.39 | -28.60 |
| Shares Outstanding | 43.20 | 22.17 |
| Earnings Per Share | -1.54 | -1.29 |
| Operating Cash Flow | -53.36 | -28.55 |
| Capital Expenditures | -0.03 | -0.05 |
| Free Cash Flow | -53.39 | -28.60 |
| Cash & Equivalents | 101 | 6.99 |
| Net Cash / Debt | 101 | 6.99 |
| Assets | 109 | 13.83 |
| Liabilities | 15.32 | 6.49 |
| Book Value | 94.07 | 7.34 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Immunovant, Inc. |
| Country |
United States |
| Employees |
51 |
| CEO |
Peter Salzmann |
Stock Information
| Ticker Symbol |
IMVT |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: IMVT |
Description
Immunovant, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.